These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31611383)

  • 1. Quantitative structural assessment of graded receptor agonism.
    Shang J; Brust R; Griffin PR; Kamenecka TM; Kojetin DJ
    Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22179-22188. PubMed ID: 31611383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand and receptor dynamics contribute to the mechanism of graded PPARγ agonism.
    Hughes TS; Chalmers MJ; Novick S; Kuruvilla DS; Chang MR; Kamenecka TM; Rance M; Johnson BA; Burris TP; Griffin PR; Kojetin DJ
    Structure; 2012 Jan; 20(1):139-50. PubMed ID: 22244763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ.
    Shang J; Brust R; Mosure SA; Bass J; Munoz-Tello P; Lin H; Hughes TS; Tang M; Ge Q; Kamenekca TM; Kojetin DJ
    Elife; 2018 Dec; 7():. PubMed ID: 30575522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
    Ohashi M; Gamo K; Oyama T; Miyachi H
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
    Ohashi M; Oyama T; Miyachi H
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives.
    Lather V; Kairys V; Fernandes MX
    Chem Biol Drug Des; 2009 Apr; 73(4):428-41. PubMed ID: 19243388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site.
    Jang JY; Koh M; Bae H; An DR; Im HN; Kim HS; Yoon JY; Yoon HJ; Han BW; Park SB; Suh SW
    Biochim Biophys Acta Proteins Proteom; 2017 Jun; 1865(6):674-681. PubMed ID: 28342850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining a conformational ensemble that directs activation of PPARγ.
    Chrisman IM; Nemetchek MD; de Vera IMS; Shang J; Heidari Z; Long Y; Reyes-Caballero H; Galindo-Murillo R; Cheatham TE; Blayo AL; Shin Y; Fuhrmann J; Griffin PR; Kamenecka TM; Kojetin DJ; Hughes TS
    Nat Commun; 2018 May; 9(1):1794. PubMed ID: 29728618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
    Gani OA; Sylte I
    Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A molecular switch regulating transcriptional repression and activation of PPARγ.
    Shang J; Mosure SA; Zheng J; Brust R; Bass J; Nichols A; Solt LA; Griffin PR; Kojetin DJ
    Nat Commun; 2020 Feb; 11(1):956. PubMed ID: 32075969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural mechanism underlying ligand binding and activation of PPARγ.
    Shang J; Kojetin DJ
    Structure; 2021 Sep; 29(9):940-950.e4. PubMed ID: 33713599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
    Sheu SH; Kaya T; Waxman DJ; Vajda S
    Biochemistry; 2005 Feb; 44(4):1193-209. PubMed ID: 15667213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S
    Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ.
    Jang JY; Bae H; Lee YJ; Choi YI; Kim HJ; Park SB; Suh SW; Kim SW; Han BW
    Sci Rep; 2018 Jan; 8(1):31. PubMed ID: 29311579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights for the design of new PPARgamma partial agonists with high binding affinity and low transactivation activity.
    Guasch L; Sala E; Valls C; Blay M; Mulero M; Arola L; Pujadas G; Garcia-Vallvé S
    J Comput Aided Mol Des; 2011 Aug; 25(8):717-28. PubMed ID: 21691811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INT131: a selective modulator of PPAR gamma.
    Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
    J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation.
    Jang JY; Kim H; Kim HJ; Suh SW; Park SB; Han BW
    Sci Rep; 2019 Aug; 9(1):11168. PubMed ID: 31371757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective binding of the fluorescent dye 1-anilinonaphthalene-8-sulfonic acid to peroxisome proliferator-activated receptor gamma allows ligand identification and characterization.
    Zorrilla S; Garzón B; Pérez-Sala D
    Anal Biochem; 2010 Apr; 399(1):84-92. PubMed ID: 20025845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A structural mechanism for directing corepressor-selective inverse agonism of PPARγ.
    Brust R; Shang J; Fuhrmann J; Mosure SA; Bass J; Cano A; Heidari Z; Chrisman IM; Nemetchek MD; Blayo AL; Griffin PR; Kamenecka TM; Hughes TS; Kojetin DJ
    Nat Commun; 2018 Nov; 9(1):4687. PubMed ID: 30409975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.